Last reviewed · How we verify
JNJ-56021927 240 Milligram
JNJ-56021927 240 Milligram is a Small molecule drug developed by Janssen Pharmaceutical K.K.. It is currently in Phase 1 development. Also known as: apalutamide.
At a glance
| Generic name | JNJ-56021927 240 Milligram |
|---|---|
| Also known as | apalutamide |
| Sponsor | Janssen Pharmaceutical K.K. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Hot Flush
- Fatigue
- Rash
- Covid-19
- Arthralgia
- Alopecia
- Nausea
- Muscle Spasms
- Dizziness
- Insomnia
- Hypertension
- Vertigo
Key clinical trials
- A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (PHASE2)
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC (PHASE3)
- A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (PHASE3)
- An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) (PHASE3)
- A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC) (PHASE4)
- A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer (PHASE1)
- A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PHASE3)
- A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JNJ-56021927 240 Milligram CI brief — competitive landscape report
- JNJ-56021927 240 Milligram updates RSS · CI watch RSS
- Janssen Pharmaceutical K.K. portfolio CI
Frequently asked questions about JNJ-56021927 240 Milligram
What is JNJ-56021927 240 Milligram?
JNJ-56021927 240 Milligram is a Small molecule drug developed by Janssen Pharmaceutical K.K..
Who makes JNJ-56021927 240 Milligram?
JNJ-56021927 240 Milligram is developed by Janssen Pharmaceutical K.K. (see full Janssen Pharmaceutical K.K. pipeline at /company/janssen-pharmaceutical-k-k).
Is JNJ-56021927 240 Milligram also known as anything else?
JNJ-56021927 240 Milligram is also known as apalutamide.
What development phase is JNJ-56021927 240 Milligram in?
JNJ-56021927 240 Milligram is in Phase 1.
What are the side effects of JNJ-56021927 240 Milligram?
Common side effects of JNJ-56021927 240 Milligram include Hot Flush, Fatigue, Rash, Covid-19, Arthralgia, Alopecia.
Related
- Manufacturer: Janssen Pharmaceutical K.K. — full pipeline
- Also known as: apalutamide
- Compare: JNJ-56021927 240 Milligram vs similar drugs
- Pricing: JNJ-56021927 240 Milligram cost, discount & access